candesartan has been researched along with probucol in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Benedict, CR; Katagiri, T; Pakala, R; Watanabe, T | 1 |
| Iida, H; Iwami, T; Mochizuki, M; Ogawa, H; Takaki, A; Tanaka, T; Wakeyama, T | 1 |
1 trial(s) available for candesartan and probucol
| Article | Year |
|---|---|
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Compounds; Combined Modality Therapy; Coronary Restenosis; Coronary Stenosis; Drug Therapy, Combination; Female; Humans; Hyperplasia; Male; Platelet Aggregation Inhibitors; Probucol; Prospective Studies; Radiography; Risk Factors; Stents; Tetrazoles; Treatment Failure; Tunica Intima; Ultrasonography | 2003 |
4 other study(ies) available for candesartan and probucol
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation.
Topics: Acetylcysteine; Aldehydes; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Cell Division; Cells, Cultured; DNA; Drug Synergism; Flavonoids; Humans; Hydrogen Peroxide; Lipoproteins, LDL; Lysophosphatidylcholines; Muscle, Smooth, Vascular; Probucol; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Tyrphostins | 2001 |